Natera (NTRA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Voting matters and shareholder proposals
Election of three Class II directors to serve until 2029 and one Class I director to serve until 2028.
Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory vote to approve executive compensation as disclosed in the proxy statement.
Advisory vote on the frequency of future executive compensation votes.
Approval of an amendment to the 2015 Equity Incentive Plan.
Consideration of any other business that may properly come before the meeting.
Board of directors and corporate governance
Nominees for director positions include Rowan Chapman, Herm Rosenman, Jonathan Sheena (Class II), and Eric H. Rubin (Class I).
Executive compensation and say-on-pay
Advisory vote on the compensation of named executive officers.
Advisory vote on the frequency of future say-on-pay votes.
Proposal to amend the 2015 Equity Incentive Plan.
Latest events from Natera
- Record growth, innovation, and AI-driven strategies are accelerating adoption and market expansion.NTRA
Morgan Stanley 23rd Annual Global Healthcare Conference9 Jul 2026 - Record growth, innovation, and clinical momentum set the stage for major milestones in 2025.NTRA
43rd Annual J.P. Morgan Healthcare Conference 20259 Jul 2026 - Q1 2025 revenue up 37% to $502M, record oncology growth, margin at 63.1%, net loss steady.NTRA
Q1 20258 Jul 2026 - Q3 2024 revenue up 64%, margin at 62%, net loss narrows, and outlook raised.NTRA
Q3 20248 Jul 2026 - Q4 revenue up 53% to $476M, with 2025 guidance for 24% growth and margin expansion.NTRA
Q4 20248 Jul 2026 - All proposals, including director elections and equity plan amendment, were approved.NTRA
AGM 20261 Jul 2026 - Record Q1, robust clinical data, and new launches drive growth and future expansion.NTRA
Goldman Sachs 47th Annual Global Healthcare Conference 20269 Jun 2026 - Q1 2026 revenue up 39% to $697M, record test volumes, margin gains, and raised guidance.NTRA
Q1 202611 May 2026 - Proxy seeks approval for director elections, auditor, compensation, and equity plan amid strong growth.NTRA
Proxy filing23 Apr 2026